In this issue:
- Sintilimab + chemotherapy for locally advanced/metastatic oesophageal SCC
- Pembrolizumab in completely resected stage IIB or IIC melanoma
- Nivolumab + chemotherapy in resectable lung cancer
- Adjuvant durvalumab uptake after chemoradiotherapy for stage III NSCLC
- Nivolumab + ipilimumab for unresectable malignant pleural mesothelioma
- Maintenance ICIs ±pemetrexed in advanced nonsquamous NSCLC
- Nivolumab + ipilimumab vs. sunitinib in advanced RCC
- Lenvatinib ±ICI for unresectable HCC in the real world
- Pembrolizumab for advanced HCC previously treated with sorafenib
- Pembrolizumab in MSI-high advanced endometrial cancer
- Pembrolizumab for MSI-high/ mismatch repair-deficient metastatic CRC
Download PDF